Department of Neurology, First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi, China.
Department of Neurology, First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi, China.
Thromb Res. 2015 Feb;135(2):375-81. doi: 10.1016/j.thromres.2014.12.006. Epub 2014 Dec 5.
Circulating endothelial microparticles act as biological markers of endothelial function that reflect vascular injury. Here, we examined the hypothesis that the quantity of endothelial microparticles in the circulation is increased in patients with ischemic cerebrovascular diseases, and investigated the potential utility of various phenotypes of endothelial microparticles as specific biomarkers of endothelial cell dysfunction. We additionally focused on identifying endothelial microparticles that may be effectively utilized as biomarkers of stroke severity in acute ischemic stroke patients.
In total, 129 subjects, including 68 consecutive patients with acute ischemic stroke and 61 age- and sex-matched healthy controls, were included in the study. Levels of circulating endothelial microparticles (CD144+/CD41a-, CD31+CD41a-, CD62E+, Annexin V+CD62E+) and platelet-derived microparticles (CD41a+/CD144-) in platelet-free plasma of patients and controls were measured using flow cytometry.
Levels of circulating endothelial CD144+/CD41a-, CD31+CD41a-, CD62E+, and Annexin V+CD62E+microparticles, but not platelet microparticles, were significantly increased in acute ischemic stroke patients, compared with control subjects (p<0.05). Notably, levels of CD144+/CD41a- microparticles were significantly correlated with stroke severity. A mild degree of correlation was evident between Annexin V+CD62E+microparticles and stroke subtype. No association with stroke was observed for other microparticle phenotypes.
Circulating endothelial microparticle amounts are increased in acute ischemic stroke patients, compared with healthy subjects. Levels of CD144+/CD41a- microparticle, but not the other phenotypes examined, may be effectively utilized as a biomarker of ischemic severity in the clinic.
循环内皮微颗粒作为反映血管损伤的内皮功能的生物标志物发挥作用。在这里,我们检验了如下假说,即在缺血性脑血管病患者的循环中,内皮微颗粒的数量增加,并研究了内皮微颗粒的各种表型作为内皮细胞功能障碍的特异性生物标志物的潜在效用。我们还专注于鉴定可能有效用作急性缺血性脑卒中患者中风严重程度的生物标志物的内皮微颗粒。
共纳入 129 名受试者,包括 68 例连续急性缺血性脑卒中患者和 61 例年龄和性别匹配的健康对照者。使用流式细胞术测量患者和对照者血小板无血浆中循环内皮微颗粒(CD144+/CD41a-、CD31+CD41a-、CD62E+、 Annexin V+CD62E+)和血小板衍生微颗粒(CD41a+/CD144-)的水平。
与对照组相比,急性缺血性脑卒中患者循环内皮 CD144+/CD41a-、CD31+CD41a-、CD62E+和 Annexin V+CD62E+微颗粒水平显著升高(p<0.05),但血小板微颗粒水平没有升高。值得注意的是,CD144+/CD41a-微颗粒水平与中风严重程度显著相关。Annexin V+CD62E+微颗粒与中风亚型呈轻度相关。其他微颗粒表型与中风无关。
与健康受试者相比,急性缺血性脑卒中患者的循环内皮微颗粒数量增加。CD144+/CD41a-微颗粒水平,而不是检查的其他表型,可能在临床上有效地用作缺血严重程度的生物标志物。